Europe’s CGT advantage at risk
Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global leadership.
ADVERTISEMENT
About c.boehm
This author has not written his bio yet.
But we are proud to say that c.boehm contributed 5 entries already.
Entries by c.boehm
The DASbox® Mini Bioreactor System: Small scale. Big results
In the field of bioprocess research and development, precise parameter control and reproducibility are key. Another important factor for economic efficiency of a lab is an effective use of lab space. The DASbox Mini Bioreactor System combines these requirements and more with smart software solutions, parallel bioprocessing option, as well as bioreactor and application flexibility. With this concept, the DASbox Mini Bioreactor System enables you to deliver big results at small scale.
Research and Innovation as a Competitive Advantage – Legal framework for Life Sciences made in Europe
Research and innovation are considered key resources for European competitiveness – and essential location factors for research-intensive industries such as the Life Sciences. The European Union is increasingly responding to this finding with a multifaceted catalogue of regulations and measures: alongside horizontal and sector-specific legal frameworks, data-law infrastructures as well as operational initiatives are being introduced, which are intended to accelerate procedures and facilitate the translation of research into healthcare delivery and into the market.
SciVario® twin: One Controller for All Your Needs
Efficiency and flexibility are key factors to stay competitive in the bioprocess field. This is the idea behind SciVario twin, a control unit for small- and bench-scale bioprocess development and optimisation.